OPTIC: A dose-ranging study of 3 starting doses of ponatinib for chronic-phase chronic myeloid leukaemia

CANDOR updated results: KdD versus Kd in patients with RRMM according to prior lines of therapy

CANDOR trial design: Investigating KdD versus Kd in relapsed/refractory multiple myeloma

GMMG-CONCEPT: Isa-KRd in front-line treatment of high-risk myeloma

Patient reported outcomes for the CANDOR trial for multiple myeloma

Checkpoint inhibitors for the treatment of advanced hepatocellular carcinoma

Comment: JAVELIN-100 for metastatic urothelial cancer

HCRN GU16-260: Nivolumab and salvage nivolumab ipilimumab in treatment-naïve patients with advanced renal cell carcinoma

Updated results from KEYNOTE-426 for metastatic kidney cancer

3-weekly cisplatin or weekly cisplatin for squamous cell carcinoma of head and neck

ASCO 2020: Breast cancer roundup

FORTE trial: Minimal residual disease evaluation in newly diagnosed multiple myeloma